America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.87 Million USD | 42.77% |
| 2022 | 1.3 Million USD | 84.74% |
| 2021 | 709.08 Thousand USD | 322.0% |
| 2020 | 168.02 Thousand USD | 30.86% |
| 2019 | 128.4 Thousand USD | 27.73% |
| 2018 | 100.52 Thousand USD | 127.99% |
| 2017 | 44.09 Thousand USD | -91.86% |
| 2016 | 541.97 Thousand USD | 5319.75% |
| 2015 | 10 Thousand USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 175.36 Thousand USD | 1714.26% |
| 2012 | 9666.00 USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 1.84 Million USD | 1.05% |
| 2024 Q1 | 1.83 Million USD | -1.79% |
| 2024 Q2 | 1.82 Million USD | -0.81% |
| 2023 Q3 | 1.81 Million USD | 30.57% |
| 2023 FY | 1.87 Million USD | 42.77% |
| 2023 Q4 | 1.87 Million USD | 2.98% |
| 2023 Q1 | 1.36 Million USD | 3.94% |
| 2023 Q2 | 1.39 Million USD | 2.16% |
| 2022 Q3 | 1.28 Million USD | 4.9% |
| 2022 FY | 1.3 Million USD | 84.74% |
| 2022 Q4 | 1.3 Million USD | 2.24% |
| 2022 Q2 | 1.22 Million USD | 34.66% |
| 2022 Q1 | 907.08 Thousand USD | 27.92% |
| 2021 Q3 | 139.2 Thousand USD | -8.01% |
| 2021 Q2 | 151.33 Thousand USD | -11.09% |
| 2021 Q4 | 709.08 Thousand USD | 409.38% |
| 2021 FY | 709.08 Thousand USD | 322.0% |
| 2021 Q1 | 170.21 Thousand USD | 1.3% |
| 2020 Q1 | 131.15 Thousand USD | 2.14% |
| 2020 Q2 | 143.8 Thousand USD | 9.65% |
| 2020 Q3 | 145.49 Thousand USD | 1.17% |
| 2020 FY | 168.02 Thousand USD | 30.86% |
| 2020 Q4 | 168.02 Thousand USD | 15.49% |
| 2019 Q1 | 100.67 Thousand USD | 0.15% |
| 2019 FY | 128.4 Thousand USD | 27.73% |
| 2019 Q3 | 127.47 Thousand USD | 2.3% |
| 2019 Q4 | 128.4 Thousand USD | 0.73% |
| 2019 Q2 | 124.6 Thousand USD | 23.76% |
| 2018 Q1 | 50.61 Thousand USD | 14.8% |
| 2018 Q3 | 72.24 Thousand USD | 8.19% |
| 2018 FY | 100.52 Thousand USD | 127.99% |
| 2018 Q4 | 100.52 Thousand USD | 39.15% |
| 2018 Q2 | 66.77 Thousand USD | 31.92% |
| 2017 Q2 | - USD | -100.0% |
| 2017 FY | 44.09 Thousand USD | -91.86% |
| 2017 Q4 | 44.09 Thousand USD | 158.85% |
| 2017 Q3 | 17.03 Thousand USD | 0.0% |
| 2017 Q1 | 606.44 Thousand USD | 11.9% |
| 2016 Q2 | 511.85 Thousand USD | -0.92% |
| 2016 Q3 | 526.91 Thousand USD | 2.94% |
| 2016 Q4 | 541.97 Thousand USD | 2.86% |
| 2016 Q1 | 516.63 Thousand USD | 5066.35% |
| 2016 FY | 541.97 Thousand USD | 5319.75% |
| 2015 Q4 | 10 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | 10 Thousand USD | 0.0% |
| 2015 Q3 | 10 Thousand USD | 0.0% |
| 2014 Q2 | - USD | -100.0% |
| 2014 Q1 | 175.36 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2013 Q2 | 150.36 Thousand USD | 0.0% |
| 2013 Q4 | 175.36 Thousand USD | 0.0% |
| 2013 FY | 175.36 Thousand USD | 1714.26% |
| 2013 Q1 | 150.36 Thousand USD | 0.0% |
| 2013 Q3 | 175.36 Thousand USD | 16.63% |
| 2012 Q4 | - USD | -100.0% |
| 2012 Q3 | 4666.00 USD | 0.0% |
| 2012 FY | 9666.00 USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -582.581% |
| Aridis Pharmaceuticals, Inc. | 6.13 Million USD | 69.49% |
| Biora Therapeutics, Inc. | 47.42 Million USD | 96.056% |
| Bio-Path Holdings, Inc. | 113 Thousand USD | -1555.108% |
| Better Therapeutics, Inc. | 14.88 Million USD | 87.431% |
| Calithera Biosciences, Inc. | 1.66 Million USD | -12.261% |
| Comera Life Sciences Holdings, Inc. | 775.04 Thousand USD | -141.31% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 19.44 Million USD | 90.382% |
| Eloxx Pharmaceuticals, Inc. | 13.38 Million USD | 86.026% |
| Evelo Biosciences, Inc. | 51.13 Million USD | 96.343% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 50.043% |
| Finch Therapeutics Group, Inc. | 30.12 Million USD | 93.792% |
| Galera Therapeutics, Inc. | 152.29 Million USD | 98.772% |
| Innovation1 Biotech Inc. | 228.99 Thousand USD | -716.716% |
| Kiromic BioPharma, Inc. | 15.54 Million USD | 87.967% |
| Molecular Templates, Inc. | 12.23 Million USD | 84.708% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 23.17% |
| NexImmune, Inc. | 68.8 Thousand USD | -2618.063% |
| Orgenesis Inc. | 22.62 Million USD | 91.732% |
| Panbela Therapeutics, Inc. | 5.19 Million USD | 63.992% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 134.5 Million USD | 98.61% |
| Statera Biopharma, Inc. | 16.26 Million USD | 88.499% |
| TRACON Pharmaceuticals, Inc. | 968 Thousand USD | -93.21% |
| Trevena, Inc. | 35.23 Million USD | 94.692% |
| Vaxxinity, Inc. | 15.16 Million USD | 87.67% |
| Vaccinex, Inc. | 247 Thousand USD | -657.195% |
| Vicapsys Life Sciences, Inc. | 353.86 Thousand USD | -428.522% |
| Viracta Therapeutics, Inc. | 25.55 Million USD | 92.682% |
| ZIVO Bioscience, Inc. | 346.34 Thousand USD | -440.007% |